他汀类药物降低乙型肝炎病毒和丙型肝炎病毒相关肝硬化失代偿风险:一项基于人群的研究
该研究利用2000至2013年台湾全民健康保险代表性队列,纳入1350例肝硬化患者,按倾向评分匹配他汀使用者(累积限定日剂量≥28)与非使用者。结果显示他汀使用以剂量依赖方式降低失代偿、死亡和肝细胞癌风险,HBV相关肝硬化失代偿风险降低更明显,酒精相关肝硬化仅呈边缘性显著。
要点
- 他汀使用与肝硬化失代偿、死亡和肝细胞癌风险呈剂量依赖下降(趋势P分别<0.0001、<0.0001和0.009)。
- HBV相关肝硬化他汀使用者失代偿风险 adjusted HR 0.39(95%CI 0.25-0.62),HCV相关为 HR 0.51(95%CI 0.29-0.93)。
- 酒精相关肝硬化他汀使用者失代偿风险 HR 0.69(95%CI 0.45-1.07),仅为边缘性显著。
核心结论
- 他汀使用降低HBV和HCV相关肝硬化的失代偿率;酒精相关肝硬化失代偿率下降仅为边缘性显著。
研究设计与样本
- 基于台湾全民健康保险代表性队列(2000至2013年)的基于人群研究,共纳入1350例肝硬化患者。
- 他汀使用者定义为累积限定日剂量(cDDD)≥28,非使用者为<28 cDDD,通过倾向评分匹配。
主要发现
- 他汀使用以剂量依赖方式降低肝硬化患者失代偿、死亡和肝细胞癌风险(趋势P分别<0.0001、<0.0001和0.009)。
- 慢性HBV相关肝硬化他汀使用者失代偿风险 adjusted HR 0.39(95%CI 0.25-0.62)。
- HCV相关肝硬化他汀使用者失代偿风险 HR 0.51(95%CI 0.29-0.93)。
- 酒精相关肝硬化他汀使用者失代偿风险 HR 0.69(95%CI 0.45-1.07),为边缘性显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Statin use decreases the risk of decompensation and mortality in patients with cirrhosis due to hepatitis C virus (HCV). Whether this beneficial effect can be extended to cirrhosis in the general population or cirrhosis due to other causes, such as hepatitis B virus (HBV) infection or alcohol, remains unknown. Statin use also decreases the risk of hepatocellular carcinoma (HCC) in patients with chronic HBV and HCV infection. It is unclear whether the effect can be observed in patients with pre-existing cirrhosis. The goal of this study was to determine the effect of statin use on rates of decompensation, mortality, and HCC in HBV-, HCV-, and alcohol-related cirrhosis. Patients with cirrhosis were identified from a representative cohort of Taiwan National Health Insurance beneficiaries from 2000 to 2013. Statin users, defined as having a cumulative defined daily dose (cDDD) ≥28, were selected and served as the case cohort. Statin nonusers (<28 cDDD) were matched through propensity scores. The association between statin use and risk of decompensation, mortality, and HCC were estimated. A total of 1350 patients with cirrhosis were enrolled. Among patients with cirrhosis, statin use decreased the risk of decompensation, mortality, and HCC in a dose-dependent manner (P for trend <0.0001, <0.0001, and 0.009, respectively). Regression analysis revealed a lower risk of decompensation among statin users with cirrhosis due to chronic HBV (adjusted hazard ratio [HR], 0.39; 95% confidence interval [CI], 0.25-0.62) or HCV infection (HR, 0.51; 95% CI, 0.29-0.93). The lowered risk of decompensation was of borderline significance among statin users with alcohol-related cirrhosis (HR, 0.69; 95% CI, 0.45-1.07). CONCLUSION: Statin use decreases the decompensation rate in both HBV- and HCV-related cirrhosis. Of borderline significance is a decreased decompensation rate in alcohol-related cirrhosis. (Hepatology 2017;66:896-907).
引用
- Chang FM, Wang YP, Lang HC, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study. Hepatology. 2017. PMID: 28318053. doi:10.1002/hep.29172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。